1077.7000 -8.10 (-0.75%)
NSE May 29, 2026 15:31 PM
Volume: 4.6M
 

Motilal Oswal
Zydus LifeSciences (ZYDUSLIF) delivered a better-than-expected financial performance in 4QFY26, with 9.5%/19%/11% beat on revenue/EBITDA/PAT.
Deven Choksey downgraded Zydus Lifesciences Ltd. to Accumulate with a price target of 1135.0 on 25 May, 2026.
More from Zydus Lifesciences Ltd.
Recommended